Fig. 5.

The effects of varlitinib and infigratinib on signalling proteins, cell proliferation, hypoxia, and intra-tumoral blood vessels. Mice bearing HCC26-0808A, HCC17-0211, and HCC01-0909 tumours were treated for 14 days, and the tumour lysate was subjected to Western blot analyses. The treatments were initiated when the tumours reached approximately 100–150 mm³. The membranes were incubated with the indicated antibodies, and representative blots are shown (A). Tissue sections from the HCC17-0211 tumour were stained for p-Histone H3, cleaved PARP, CD31, and hypoxia (HypoxyProbe) (B)